attend 2023 ASCO® Annual Meeting
NeoGenomics is thrilled to
exhibit at the 2023 ASCO® Annual Meeting taking place June 2 - 6,
2023 in Chicago, Illinois. Experts will be holding Q&A sessions in the
NeoGenomics booth #5135 to discuss key data from the abstracts being presented.
Topics will include their experience with the RaDaR® assay, a liquid
biopsy test for molecular/minimal residual disease (MRD) as well as MultiOmyx™.
MultiOmyx is NeoGenomics’ proprietary, multiplexed immunofluorescence platform
that enables single-cell quantification and advanced spatial analysis for up to
60 proteins in a single FFPE tissue section.
more or RSVP for one of the presentations, click
Effective Monday, June 5th, the PD-L1
SP263 FDA (TECENTRIQ®) for NSCLC test name will
be changed to PD-L1
SP263 FDA for NSCLC.
- This test is now the
companion diagnostic (CDx) for a second drug, LIBTAYO®
(cemiplimab-rwlc). The FDA approved the label expansion for the VENTANA
PD-L1 (SP263) Assay on March 6, 2023.
- Test results will now refer
to both therapies and their associated cut-offs; ≥ 1% of tumor cells of
any intensity for TECENTRIQ® (atezolizumab) and ≥ 50% of tumor
cells (TC) of any intensity for LIBTAYO® (cemiplimab-rwlc).
Effective Monday, June 5th, the NeoTYPE®
HRD+ Profile test name will be changed to NeoTYPE® HRR
- This change will more closely
reflect the reporting output of this test which are gene mutations
associated with the homologous recombination repair (HRR) pathways,
providing information on if cancer has resulted due to the difficulty in
repairing this type of DNA damage known as HRD (homologous recombination
- Knowing HRR gene mutation
status is important for PARP inhibition targeting in a variety of tumor
types including breast, ovarian, pancreatic, and prostate.
Test requisitions will reflect
both of these test name changes in the next revision update scheduled for the
alpha (FRα) is a new actionable biomarker in ovarian cancer.
NeoGenomics offers the FOLR1 IHC
test. Testing for FRα
expression is performed using the FDA-approved immunohistochemistry (IHC)
companion diagnostic (CDx)—VENTANA
FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment
with the associated biomarker-driven therapy.
To support physicians in determining FRα expression in their ovarian cancer patients, ImmunoGen is
providing a sponsored, no-charge, third-party IHC testing program for patients
with a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer.
To learn more about this program, visit our website.
the list of interface-related test changes that will occur on Monday June
5th, click here
for a downloadable document to view the impacted interface test codes